John Waddell, Reid Philips, Tyler Holck, Gail Anderson. AASV. 2008
Porcine reproductive and respiratory syndrome (PRRS) in growing pigs is estimated to cost $5.60 - $7.60 per pig sold. Experimental studies have demonstrated that modified-live PRRS virus (PRRSv) vaccines stimulate a protective immune response against heterologous PRRSv challenge in growing pigs resulting in a significant reduction of PRRS-associated lung lesions, clinical disease, and a significant improvement in average daily weight gain.
The present field study evaluated the impact of a modified-live PRRSv vaccine (Ingelvac PRRS ATP, Boehringer Ingelheim Vetmedica, Inc., St Joseph, MO) for control of naturally occurring heterologous PRRSv infection in nursery pigs as part of a comprehensive PRRS management strategy which also included improvement in needle management, transportation and biosecurity procedures.